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Transplantation, Benjamin et al. report the results of non-
myeloablative hematopoietic stem cell transplantation
(HSCT) for patients with myelodysplastic syndrome and
myeloproliferative neoplasms after conditioning with total
lymphoid irradiation (TLI) and antithymocyte globulin (ATG)
[1]. The present report follows their previous reports of the
use of TLI-ATG conditioning for the transplantation in pa-
tients with lymphoid malignancies and acute leukemia [2,3].
The recipients of the TLI-ATG regime have been character-
ized by an extremely low incidence of acute graft-versus-
host disease (GVHD) but a normal incidence of chronic
GVHD. In the previous reports, the establishment of com-
plete (> 95% donor T lymphocyte) chimerism has been
associated with a reduced incidence of relapse, especially
among recipients with lymphoid malignancies, regardless of
their pre-HSCT status, whereas recipients with mixed
chimerism (< 95% donor T lymphocytes) had a high rate of
relapse. The same differences were seen in recipients with
acute leukemia (an increased rate of relapse in recipients
with mixed chimerism), although the overall relapse rates
were higher.
In the present study, the impact of both donor myeloid
and lymphoid chimerism on the likelihood of relapse was
examined. As in the previous studies, the presence of com-
plete donor T lymphocyte chimerism was predictive of a
decreased likelihood of relapse. Interestingly, the assessment
of myeloid chimerism (CD15þmyeloid cells) determined that
the presence of complete donor myeloid chimerism (> 95%
donor CD15þ cells) was more predictive of a sustained
remission than even complete donor T lymphocyte chime-
rism. The impact of myeloid chimerism as a predictor of the
probability of relapse after TLI-ATG conditioning has not
been previously reported.
The basis for the protective effect of TLI-ATG against acute
GVHD has been the subject of extensive preclinical evalua-
tions, primarily in mice and in some human studies [4-6].
Central to the establishment of donor engraftment, with
either complete or mixed chimerism, is the role of natural
killer cells that express an invariant TCR receptor (iNKTcells).
The recipient iNKT cells are relatively radioresistant, and,
therefore, their relative frequency is markedly increased af-
ter TLI-ATG conditioning even though there is overallFinancial disclosure: See Acknowledgments on page 751.
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cells isolated from the cytokine-mobilized donor peripheral
blood stem cells plus deﬁned doses of CD3 T lymphocytes,
which contain iNKT cells. Both donor and recipient iNKT cells
are essential for the establishment of donor hematopoietic
stem cell engraftment without the development of acute
GVHD. The iNKT cells are activated by the TLI and other
agents to produce IL-4, which activates both donor and
recipient regulatory T lymphocytes (Treg), which then pro-
duce the immunosuppressant molecule, IL-10, resulting in a
lack of donor hematopoietic stem cell rejection. Murine ex-
periments have deﬁned the absolute requirement for donor
and recipient iNKT cells, IL-4, Treg lymphocytes, and IL-10
for the establishment of either complete or mixed donor
chimerism.
Of interest is the fact that TLI-ATG conditioning has not
reduced the incidence of chronic GVHD, as most analyses of
chronic GVHD have indicated that the presence of acute
GVHD is the major predictor of chronic GVHD [7]. The pres-
ence of chronic GVHD after TLI-ATG suggests that the pre-
parative regimemay have a direct role in the pathogenesis of
chronic GVHD.
The TLI-ATG conditioning regime has also been used as
an adjunct to HSCT in the context of renal transplantation
with the goal of developing recipient tolerance to the donor
renal graft and, therefore, the possibility of withdrawing
all immunosuppressive drugs. After related renal trans-
plantation, recipients undergo conditioning with TLI-ATG
and the transplantation of deﬁned doses of CD34þ cells
isolated from mobilized donor peripheral blood stem cells
and deﬁned doses of CD3 T lymphocytes, depending upon
whether the donor is HLA identical or not [8,9]. The
recipients received routine renal transplantation immuno-
suppression, including mycophenolate mofetil and cyclo-
sporine. The establishment of sustained, but not necessarily
permanent, mixed chimerism (donor T lymphocytes < 95%
by day 100) has resulted in the complete withdrawal of all
immunosuppressive drugs in some recipients. The goal of the
TLI-ATG HSCT is not complete donor lymphoid chimerism, as
it would be associated with signiﬁcant post-transplantation
immunodeﬁciency and the possibility of opportunistic in-
fections. Recipients who do not develop mixed chimerism,
continue on their routine post-transplantation immuno-
suppression. In mice, the establishment of sustained
donor mixed donor chimerism results in bidirectional
tolerance that results in graft persistence without ongoing
immunosuppression.
Thus, the presence of mixed chimerism after HSCT is
either to be desired (as in the case of renal transplantation)
or is to be avoided (as is the case in hematological malig-
nancies), depending upon the clinical setting. The basis for
the control of the TLI-ATG regime is the quantiﬁcation of
both the hematopoietic stem cells and T lymphocyte doses,
because both can inﬂuence whether complete or mixed
chimerism is more likely to be achieved. In the future, HSCT
will have increasing use as an immunomodulatory agent, the
R. Parkman / Biol Blood Marrow Transplant 20 (2014) 749e751 751goal of which will depend upon the clinical setting. The use
of deﬁned doses of both hematopoietic stem cells and T
lymphocytes will be necessary to ﬁne-tune the degree of
donor chimerism after HSCT.
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